Why Nanobiotech?

  • Calcification and inflammation afflict most of our aging population. Nanobiotech, LLC is the only company with proven methods to show that a tiny nanoparticle known commonly as nanobacteria produces a calcified coating which is the same material as found in disease-related calcified deposits.
  • These nanobacteria have been discovered in the calcified deposits of heart disease, arthritis and kidney disease, as published in leading scientific journals. See the Publications section of our website for information. Nanobacteria is the only credible scientific evidence of a particle that provokes pathological calcification.
  • Some critics have claimed that these particles are just inorganic crystals. However, the photographic evidence alone shows these nanoparticles have a different structure than inorganic crystals. On the left are inorganic calcium phosphate crystals with their jagged and jumbled surfaces. On the right are nanobacteria. There can be no mistaking the difference. Nanobacteria have been cultured and photographed by independent researchers around the world including at Mayo Clinic. (Click image to enlarge picture).

Inorganic and nanobacteria apatite - comparison
Commercial hydroxyl apatite (A) and nanobacteria culture (B). Top: SEM (scanning electron microscope) images of samples; bottom: Ca and P peaks detected by EDX (energy-dispersive X-ray) analysis


Calcification is a Disease Condition

  • Most everyone has calcification by the time they are fifty, and the process often starts when we are teenagers. Calcification is a life-long disease process, yet its cause and cure have been mysteries to science.
  • Calcification is documented in thousands of studies as causing blockages in arteries, inflammation in joints, and disruption to cells and cellular function.
  • Until now, no medical research has shown convincingly the cause of calcification. No process or organism has been found that produces these rock-hard calcified deposits under normal blood conditions-except nanobacteria.

Nanobitech's Advantage in the Marketplace

  • Any company that discovers a cause and effective treatment for pathological calcification could be guaranteed powerful entry to markets because of the previous absence of an effective treatment.
  • Nanobiotech has a license to a compelling body of related intellectual property, including proprietary diagnostics in the marketplace now, that can recognize nanobacteria in blood and human tissue.
  • Recently, these diagnostics have shown that nanobacteria bind disease-causing proteins in uniquely identifiable combinations, opening a potentially new door to early diagnosis and differentiation of many diseases.
  • Nanobiotech  has patented a range of drug combinations, consisting of well known and safe ingredients, shown convincingly to eradicate nanobacteria in vitro, as published by the U.S. Patent and Trade Office.
  • Since 2004, published studies have shown that some combinations patented by Nanobiotech are effective at treating atherosclerosis and prostatitis where no other treatments succeeded previously.
  • From these studies, the company learned valuable information about patient compliance and drug effectiveness. No serious safety problems have been encountered. This let the company move  forward with other effective nanobiotics.

The Nanobiotech Challenge

  • Our challenge is to safely and effectively treat pathological calcification and nanobacteria-related diseases. To do that we are also characterizing more accurately the disease-causing properties of these nanobacteria/nanoparticles. The evidence suggests that we are on the right track.